Skip to main content

Wentworth Kory James's Form 4 filing

Entrada Therapeutics, Inc. (TRDA) · filed Aug 23, 2022

Accession no.
0001104659-22-093784
Filed
Aug 23, 2022
Trade date
Aug 19-23, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $152.5K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Wentworth Kory JamesCIK 0001725663Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 19, 2022Common StockMOption exerciseAcquired+4,452$2.10+$9,349.224,673Direct
Aug 19, 2022Common StockSSaleDisposed−8,529$13.08F2−$111,559.3216,144Direct
Aug 22, 2022Common StockMOption exerciseAcquired+117$2.10+$245.716,261Direct
Aug 22, 2022Common StockSSaleDisposed−217$13.00F3−$2,82116,044Direct
Aug 23, 2022Common StockMOption exerciseAcquired+1,403$2.10+$2,946.317,447Direct
Aug 23, 2022Common StockSSaleDisposed−2,909$13.09F4−$38,078.8114,538Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 19, 2022Common StockMOption exerciseDisposed−4,452$0.00$0111,444Direct
Aug 22, 2022Common StockMOption exerciseDisposed−117$0.00$0111,327Direct
Aug 23, 2022Common StockMOption exerciseDisposed−1,403$0.00$0109,924Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.34, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)